First Horizon Advisors, Inc. Seagen Inc. Transaction History

First Horizon Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$187.64 - $206.25 $9,569 - $10,518	-51 Reduced 24.88%	154 $29,000
Q4 2022 Feb 10, 2023	SELL	$117.37 - $139.17 $2,582 - $3,061	-22 Reduced 9.69%	205 $26,000
Q3 2022 Nov 09, 2022	BUY	$135.27 - $180.11 $541 - $720	4 Added 1.79%	227 $30,000
Q2 2022 Aug 02, 2022	BUY	$108.81 - $179.33 $22,850 - $37,659	210 Added 1615.38%	223 $39,000
Q1 2022 May 10, 2022	SELL	$119.61 - $157.85 $8,253 - $10,891	-69 Reduced 84.15%	13 $2,000

Q4 2021 Feb 09, 2022	SELL	$142.57 - $190.86 $4,277 - $5,725	-30 Reduced 26.79%	82 $12,000
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $74,216 - $88,476	-521 Reduced 82.31%	112 $19,000
Q3 2021 Nov 09, 2021	BUY	$142.45 - $169.82 $74,786 - $89,155	525 Added 486.11%	633 $107,000
Q2 2021 Aug 09, 2021	BUY	$135.08 - $161.1 $7,969 - $9,504	59 Added 120.41%	108 $17,000
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $8,066 - $10,384	49 New	49 $8,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.